MiR-145 expression and rare NOTCH1 variants in bicuspid aortic valve-associated aortopathy by Girdauskas, Evaldas et al.
RESEARCH ARTICLE
MiR-145 expression and rare NOTCH1
variants in bicuspid aortic valve-associated
aortopathy
Evaldas Girdauskas1,2*, Johannes Petersen1,2, Niklas Neumann1,2, Martin Ungelenk3,
Ingo Kurth4, Hermann Reichenspurner1,2, Tanja Zeller2,5
1 Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, 2 German
Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany,
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Abstract
MicroRNAs (miRNAs) may serve as elegant tool to improve risk stratification in bicuspid aor-
tic valve (BAV)-associated aortopathy. However, the exact pathogenetic pathway by which
miRNAs impact aortopathy progression is unknown. Herewith, we aimed to analyze the
association between circulating miRNAs and rare variants of aortopathy-related genes. 63
BAV patients (mean age 47.3±11.3 years, 92% male) with a root dilatation phenotype, who
underwent aortic valve+/-proximal aortic surgery at a single institution (mean post-AVR fol-
low-up 10.3±6.9 years) were analyzed. A custom-made HaloPlex HS panel including 20 aor-
topathy-related genes was used for the genetic testing. miRNAs were extracted from whole
blood and miRNA analysis was performed using miRNA-specific assay. Study endpoint was
the association between circulating miRNAs and rare genetic variants in the aortopathy
gene panel. The study cohort was divided into a subgroup with rare variants vs. a subgroup
without rare variants based on the presence of rare variants in the respective genes (i.e., at
least one variant present). The genetic analysis yielded n = 6 potentially and likely patho-
genic rare variants within the NOTCH1 gene as being the most common finding. Univariate
analysis between blood miRNAs and NOTCH1 variants revealed a significantly lower
expression of miR-145 in the subgroup of patients with NOTCH1 variants vs. those without
NOTCH1 variants (i.e., delta Ct 4.95±0.74 vs. delta Ct 5.57±0.78, p = 0.04). Our preliminary
data demonstrate a significant association between blood miR-145 expression and the pres-
ence of rare NOTCH1 variants. This association may be indicative of a specific pathogenetic
pathway in the development of genetically-triggered bicuspid aortopathy.
Introduction
Dilatation of the proximal aorta, so-called bicuspid aortopathy, is present in approximately
one half of the bicuspid aortic valve (BAV) patients and might be associated with an
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increased rate of adverse aortic events (i.e., aortic dissection / rupture) [1]. Cross-sectional
aortic diameter has been traditionally used in the decision-making process regarding need
of aortic surgery [2]. However, this parameter is obviously of limited value to predict the
risk of adverse aortic events [3,4]. Phenotypic heterogeneity in BAV disease has been
increasingly recognized during the last decade [5,6] and recent efforts have been focused on
the identification of markers of progressive aortopathy [7]. In particular, microRNAs (miR-
NAs) have been suggested to be of potential value when diagnosing a progressive aneurys-
mal disease [7,8].
Although miRNAs have already been shown to be associated with bicuspid aortopathy [9],
the specific molecular mechanisms by which miRNAs impact the development of aortopathy
are still poorly understood. Here, we aimed to examine the association between specific blood
miRNAs and rare genetic variants in candidate genes known to be associated with aortopathy
and BAV, and to investigate their association with the severity of aortopathy.
Methods
Study population
Patients with isolated / predominant BAV insufficiency and aortic root dilation (i.e., so-called
BAV root phenotype) were considered for this study. Patients with aortic stenosis (i.e., mean
transvalvular pressure gradient 20.0 mmHg) were excluded. These inclusion criteria resulted
in a total of 63 patients who were available for this study.
All 63 patients underwent a cross-sectional telephone-based follow-up (mean post-AVR
follow-up 10.3 ± 4.9 years (range 0–19 years). Subsequently, these patients received a written
follow-up questionnaire and were asked to answer specific questions regarding their family
history of BAV and aortopathy. Follow-up visits were scheduled and included non-invasive
proximal aortic imaging (transthoracic echocardiography and aortic CT/MRI) as well as
peripheral blood sampling.
The study was approved by the ethics committee of the Medical Association Thuringia,
Nr. 23333/2014/146 and each individual patient gave a written informed consent. The data for
this study will be made available upon request, Due to ethical restrictions, data cannot be de-
identified and data sharing is not allowed by the ethics committee of the Medical Association
Thuringia, as well as due to restrictions of the data protection regulations of the European
Commission. The contact person for data access is Beatrix Mattes (b.mattes@uke.de), current
data trustee of the University Heart Center, Hamburg.
Definitions and measurements
BAV was suspected if 2-dimensional echocardiographic short-axis imaging of the aortic valve
demonstrated the existence of only two commissures delimiting two aortic valve cusps. The
final decision regarding the bicuspidality of aortic valve was made based on the intraoperative
description of valve anatomy by the attending surgeon. Sievers’ classification was used when
classifying the bicuspid aortic valves [10]. Aortic valve insufficiency was quantified using the
published echocardiography guidelines [11].
Proximal aortic diameters were assessed by multiple echocardiographic measurements in
the parasternal long-axis view. All patients with aortic root diameter of 40.0 mm, as diag-
nosed by transthoracic echocardiography, underwent preoperative computed tomography
(CT) or magnetic resonance imaging (MRI) of the thoracic aorta and aortic dimensions were
measured in accordance to previously published recommendations [12].
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Genetic analysis
Details of the genetic analyses performed has been described before [13]. Briefly, a total of 20
candidate genes associated with BAV aortopathies were included in a custom aortopathy gene
panel: ACTA2, AXIN1, ELN, FBN1, FGF8, FN1, GATA5, HOXA1, KCNJ2, MMP9, MYH11,
NKX2-5, NOS3, NOTCH1, PDIA2, SMAD6, TGFB1, TGFB2, TGFBR1 and UFD1L. This aortopa-
thy gene panel was designed based on data from the literature reporting genetic abnormalities
in patients with BAV aortopathy and included the genes that were reported most consistently
[1, 6, 14, 15]. Reported genetic variants of the aortopathy gene panel include only those listed in
the ExAC database with an allele frequency of<0.01 or those that were not listed at all. The
pathogenicity of the variants on the aortopathy gene panel was assessed using in silico prediction
tool analysis (PolyPhen, MutationTaster, SIFT and LRT). Predicted effects of all potentially or
likely pathogenic variants on the protein level are presented in our previous manuscript (13).
Depending on the presence of rare variants, the study cohort was divided into a subgroup of
patients with and without rare variants based on the presence of rare variants within the respec-
tive genes (i.e. at least one variant present) and were named e.g. NOTCH1(+) variant and
NOTCH1(-) variant subgroups. Information on rare NOTCH1 variants are provided in S1 File
and Table A in S1 File.
miRNA analysis
Blood samples for miRNA analysis were collected the day before surgery. Total RNA was iso-
lated from frozen whole blood samples using the PAXgene Blood miRNA kit (Qiagen, Hilden,
Germany) according to the manufactures recommendation. Purification was carried out auto-
mated on a QIAcube system (Qiagen, Hilden Germany). Concentration of isolated RNA was
measured on a NanoDrop N1000 System (peqlab) and 10ng of isolated RNA was used for
miRNA analyses.
miRNAs to be analyzed were selected from the literature based on their previously reported
association with aortopathies [9,16]. The following miRNAs were assessed: miR-1, miR-17,
miR-18a, miR-19a, miR-20a, miR-21, miR-29b, miR-106a, miR-133a, miR-143, miR-145. For
normalization, miR-16 was used.
cDNA synthesis and miRNA analysis were performed using the TaqMan Advanced miRNA
cDNA Synthesis Kit (ThermoFisher Scientific) and miRNA-specific TaqMan Advanced
miRNA assays (ThermoFisher Scientific) on a 7900 HT Real Time System and Ct-values were
normalized to miR-16 by the formula 2-(Ct[miRNA]-Ct[miR-16]) for Ct<40. In the case Ct value
were40, miRNAs were considered as undetermined.
Control group
To validate our findings, we included a control group of 50 tricuspid aortic valve (TAV)
patients without aortopathy who underwent aortic valve surgery due to valvular stenosis or
insufficiency during the same study period. Measurements of circulating miR-145 values as
well as genetic analysis of rare NOTCH1 gene variants which were previously identified in the
study group was performed in this control group (n = 50). miRNA analysis was performed as
described for the BAV study group. For genetic analyses of NOTCH1 variants in the control
group de novo genotyping of the following SNPs was performed using 50 nuclease assays
according to the manufacturers´ recommendations (TaqMan assay, Applied Biosystems,
Darmstadt): rs138504021 (c.4028C>T), rs201779159 (c.5414T>C). For rs752919688
(c.1334C>T) no reliable assay, i.e. primers and probes, could be generated.
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Statistics
Categorical variables are presented as percentages and continuous variables are expressed as
mean ± standard deviation (SD). All statistical analyses were performed with the IBM SPSS 22.0
software (IBM Corp, New York, USA). Delta CT values of analyzed miRNAs were compared
for differences using unpaired two-tailed t-test. The correlation analyses were performed using
Pearson correlation coefficient. All p values of< 0.05 were considered statistically significant.
Univariate analysis was performed to analyze the potential impact of demographic parame-
ters (age, gender), presence of co-morbidities (diabetes, chronic pulmonary disease, smoking,
chronic renal failure), and the presence of rare NOTCH1 variants on the expression patterns of
circulating miRNAs.
Results
Characteristics of study participants
Demographics and intraoperative variables are summarized in Table 1. Our study cohort con-
sisted of young, almost exclusively male patients with BAV insufficiency and aortic root dilata-
tion, which underwent an aortic valve with/without aortic root surgery.
Detection and correlation analyses of microRNAs
Four miRNAs (miR-1, miR-29b, miR-133a, and miR143) were undetectable. Results from the
correlation analysis among the remaining miRNAs are presented in Fig 1. Although the values
Table 1. Demographics and intraoperative variables.
Variable Study cohort
(n = 63)
Mean age (years) 47.3± 11.3
Male 58 (92)
BSA (m2) 1.99± 0.7
FA of aortopathy/ SCD 8 (13)
NYHA† class III / IV 27 (43)
Aortic root (mm) 48.1 ± 9.3
Arterial hypertension 38 (60)
Diabetes 3 (5)
History of smoking 34 (55)
Peripheral arterial disease 0 (0)
COPD ‡ 2 (4)
Aortic valve repair 13 (21)
Composite graft replacement 21 (33)
Isolated AVR surgery 29 (46)
CPB time (min) k 84.0 ± 13.1
Cross-clamp time (min) 52.0 ± 8.2
Mean prosthesis size (mm) 27.8± 1.3
Mechanical prosthesis 38 (60)
Data presented as numbers (%) or as mean ± SD; FA -family anamnesis
—body surface area
—sudden cardiac death
† - New York Heart Association class
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of most miRNAs correlated significantly, the strongest correlation was found between miR-17
and miR-106a (r = 0.84, p<0.001), miR-17 and miR-18a (r = 0.60, p<0.001) as well as between
miR-145 and miR-20a (r = 0.58, p<0.001).
There was no significant association between the levels of the miRNAs and gender, different
age profiles, and comorbidities. A significant inverse linear correlation was found between cir-
culating miR-145 values and ascending aorta diameter (r = -0.25, p = 0.02).
Fig 1. Correlation of individual microRNAs.
https://doi.org/10.1371/journal.pone.0200205.g001
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Genetic analysis and NOTCH1 variants
A total of 10 rare genetic variants in the NOTCH1 gene were identified in our study cohort,
with six of them classified as potentially and likely pathogenic based on in-silico prediction tool
analysis (Table 2).
All six NOTCH1 gene missense variants resulted in a change of one amino acid in the
NOTCH1 protein structure. Five of the six NOTCH1 variants are located within the extracellular
domain. In fact, c.1334C>T (p.T445M), c.1862G>A (p.R621H), c.4028C>T (p.A1343V) and
c.4168C>A (p.P1390T) affect epidermal growth factor (EGF)-like domains. Each EGF-like repeat
is composed of approximately 40 amino acids, and its structure is defined largely by six conserved
cysteine residues that form three conserved disulfide bonds. Three of the detected changes,
c.1862G>A (p.R621H), c.4028C>T (p.A1343V), and c.4492A>G (p.K1498E) are in close prox-
imity to one of the cysteines. The alteration of the amino acid sequence might also alter the capa-
bility to create disulfide bonds and thus impair ligand binding. In addition, each EGF-like repeat
can be modified by O-linked glycans at specific sites. The c.1334C>T (p.T445M) variant at such a
conserved site that is predicted to undergo glycosylation might well affect protein function [17].
The mutation c.4492A>G:(p.K1498E) is located in the LNR2 domain. The LNR (Lin-12/Notch
repeat) region is a hallmark of the Notch receptor family and is involved in Notch signaling. An
altered amino acid sequence might prevent the initiation of the ligand-induced proteolytic cleav-
age and release of the intracellular regulatory domain. The functional consequence of the intracel-
lularly located c.5414T>C (p.L1805P) variant is difficult to predict, however, the incorporation of
a proline may impact the secondary structure of the protein.

























- previously published pathogenic variants in association with clinical phenotype
https://doi.org/10.1371/journal.pone.0200205.t002
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Clinical characteristics and severity of BAV-associated aortopathy were compared between
the patients’ subgroup with identified NOTCH1 gene variants (i.e., at least one potentially or
likely pathogenic NOTCH1 variant, n = 5) and the subgroup without pathogenic NOTCH1 var-
iants (n = 58). No clinically relevant differences could be identified between NOTCH1(+) vari-
ant and NOTCH1(-) variant subgroups in terms of age at presentation (i.e. 52.1 ± 11.4 years vs
47.3 ± 11.2 years, P = 0.4), pre-AVR aortic dimensions (i.e. 45.3 ± 12.1mm vs 48.1 ± 8.3,
P = 0.4) and family history of BAV/aortopathy. Of note, all NOTCH1 (+) patients had an iso-
lated aortic valve regurgitation and dilation of the aortic root. Except for the raphe region,
there were no major calcifications in the aortic cusps or severe stenotic component of the aor-
tic valve lesion.
Association between miRNA expression and NOTCH1 variants
We analyzed the association between the presence of NOTCH1 variants and miRNA expres-
sion. A significantly lower expression of blood miR-145 was found in the subgroup with
NOTCH1 variants as compared to patients without NOTCH1 variants (delta Ct 4.95±0.74 vs.
delta Ct 5.57±0.78, p = 0.045) (Table 3, Fig 2). The remaining miRNAs demonstrated no sig-
nificant differences in the expression patterns between NOTCH (+) and NOTCH (-)
subgroups.
miR-145 expression and the progression of aortic root diameter
To analyze the potential relation of miR-145 to the development of BAV aortopathy, we exam-
ined the association between expression of blood miRNAs and clinical markers of aortopathy
progression.
The progression of aortic root diameter was assessed in the subgroup of 39 (46%) BAV root
phenotype patients who did not receive an aortic root surgery (i.e., an isolated aortic valve
replacement only). The mean length of MRI follow-up was 11.1 ± 5.5 years (a total of 312
patient-years). An MRI-defined progression of aortic root diameter 3.0 mm (i.e., measured
at the level of the sinus of Valsalva) was revealed in 7 post-AVR patients with a range of pro-
gression being between 3.0–12.0 mm.
A significant association between miR-145 as well as miR-17/miR-106a and the progression
of aortic disease was observed. The values of miR-145 (5.48±0.79 vs. 6.21±1.12, p = 0.04) and
miR-17/miR-106a (1.63±0.42 vs. 2.11±0.63, p = 0.044) were significantly lower in patients who
experienced aortopathy progression (i.e., diameter increase 3mm) vs. those with “stable”
aortic diameters (i.e., diameter increase < 3mm) (Table 4). Of note, 4 of the 39 followed
patients had pathogenic NOTCH1 variants and all of them were male.
Table 3. Expression of microRNAs in patients with and without potentially/likely pathogenic NOTCH1 variants. Normalized delta Ct values are shown.
miR Whole cohort, (n = 63) NOTCH1 (+) subgroup, (n = 5) NOTCH1 (-) subgroup, (n = 58) p value
miR-145 5.52±0.79 4.95±0.74 5.57±0.78 0.045
miR-21 5.30±0.73 5.73±0.78 5.26±0.73 0.173
miR-17 1.91±0.65 2.23±0.73 1.88±0.65 0.254
miR-19a 6.26±1.46 5.74±0.78 6.30±1.17 0.291
miR-20a 5.08±1.13 4.63±1.17 5.12±1.13 0.360
miR-18a 7.12±1.46 5.81±3.29 7.24±1.18 0.388
miR-106a 5.77±0.52 5.86±0.35 5.76±0.53 0.673
—delta CT values, normalized for miR-16 values
- p value for comparison NOTCH1 (+) vs. NOTCH1 (-)
https://doi.org/10.1371/journal.pone.0200205.t003
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Furthermore, a correlation analysis between the levels of circulating miR-145 and the abso-
lute aortic diameter in the subgroup of 39 patients who did not receive aortic surgery showed a
significant moderate inverse correlation between these two variables (r = -0.48, p = 0.03).
Comparison with TAV group
None of the rare NOTCH1 variants could be identified in the control group of TAV patients
without aortopathy. Simultaneously, the expression of circulating miR-145 was significantly
higher in the TAV control group vs. BAV study group (i.e., 25.9 ± 3.9 vs. 20.7 ± 0.6, p<0.001).
Discussion
The primary aim of this project was to examine the association between specific miRNAs and
rare genetic variants known to be related to aortopathy and to investigate the association of
miRNAs and the severity of aortopathy.
Fig 2. Expression of miR-145 in patients with and without rare NOTCH1 variants.
https://doi.org/10.1371/journal.pone.0200205.g002
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Our main results show that i) miR-145 is associated with rare genetic variants within the
NOTCH 1 gene and ii) that miR-145 correlates with the progression of bicuspid aortopathy
during the follow up. While our previous publication [13] focused primarily on the whole
spectrum of rare genetic variants in BAV patients, without addressing biomarkers and without
analyzing the pathogenetic linkage between NOTCH1 variants, circulating miRNAs and aor-
topathy, our current manuscript aims to establish a potential pathogenetic pathway in the
development of BAV aortopathy and therefore presents the subsequent and in-depth analysis
of the previously identified rare genetic variants.
The pathogenesis of BAV-associated aortopathy is incompletely understood. Hemody-
namic effects and primary genetic disorder have been proposed to interact to various degree,
simultaneously causing the progression of BAV-associated aortopathy [1]. Traditional criteria
based on the aortic size are insufficient to reliably stratify the complication risk in BAV aorto-
pathy [3,4]. Therefore, circulating biomarkers and in particular miRNAs may be valuable tools
to improve the prediction of aortic events in BAV disease [7–9]. However, the pathogenetic
pathways by which miRNAs are involved in the development of aortopathy are still poorly
understood [18,19].
Patients included in this study were BAV root phenotype patients who are known to have
the most aggressive form of aortopathy and a predominantly genetically-triggered aortic dis-
ease [5,20]. Recent studies reported genetic abnormalities in TGFBR2, FBN1, NOTCH1 and
SMAD2 genes in this specific patient cohort [14], while the clinical data indicated an increased
risk of life-threatening aortic events after an isolated aortic valve surgery [20] suggesting a rela-
tion between the molecular mechanisms linked to these genes and the severity of aortic events.
Of main interest is the finding of a significant association between rare variants in the
NOTCH1 gene and the expression of miR-145 and the significant association of miR-145 and
aortopathy progression during the follow-up. NOTCH1 signaling network is an evolutionary
conserved intercellular signaling pathway that plays a role in a variety of developmental pro-
cesses by controlling cell fate decisions. It is involved in the angiogenesis and negatively regu-
lates endothelial cell proliferation and migration as well as the angiogenic sprouting.
Our findings are in accordance with previous studies showing that miRNAs are downregu-
lated in progressive vasculopathies [16]. Specifically, miR-145 has previously been shown to
influence vascular smooth muscle cell (VSMC) differentiation through post-transcriptional
repression of proliferation-associated proteins and thereby has implications for vascular dis-
eases [16,21]. Expression of miR-145 was significantly downregulated in the vascular walls
with neointimal lesion formation and in cultured dedifferentiated VSMCs [21]. Based on these
findings, miR-145 has been proposed as a novel phenotypic modulator of VSMCs [21].
Table 4. Expression of microRNAs in patients with and without aortopathy progression. Normalized delta Ct values are shown.
MicroRNA Aortic surgery (-), (n = 39) Progressive aortopathy, (n = 7) Stable aortopathy, (n = 32) p value
miR-106a 5.84±0.44 5.48±0.37 5.92±0.42 0.023
miR-145 5.61±0.85 5.48±0.79 6.21±1.12 0.04
miR-17 2.04±0.63 1.63±0.42 2.11±0.63 0.044
miR-19a 6.22±0.96 5.81±0.62 6.28±1.02 0.295
miR-20a 5.06±1.21 5.30±0.87 4.92±1.25 0.479
miR-21 5.36±0.63 5.21±0.84 5.39±0.62 0.557
miR-18a 7.00±1.72 7.27±0.48 6.90±1.92 0.640
—delta CT values, normalized for miR-16 values
- p value for comparison progressive aortopathy vs. stable aortopathy
https://doi.org/10.1371/journal.pone.0200205.t004
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Furthermore, Boucher et al. proposed a potential linkage between miR-145 expression and
the NOTCH signaling [18]. The authors suggested a common signaling pathway that promotes
the VSMC contractile phenotype, including an increased NOTCH signaling and simultaneous
upregulation of miR-145 expression, and leads to an increased differentiation and decreased
proliferation [18]. Conversely, the inhibition of basal NOTCH signaling is associated with
decreased levels of miR-145 [18]. In accordance to these findings, we found a decreased miR-
145 expression in the study subgroup with rare variants of NOTCH1 gene. Rare NOTCH1 gene
variants, as identified in this study, may cause deleterious effects on the protein structure and
therefore be responsible for attenuated basal NOTCH signaling which may be associated with
the decreased miR-145 levels and resulting progression of aortopathy. Most of the detected
NOTCH1 variants are located within important ligand binding domains. Interfering with the
capability to form disulfide bonds or disrupting proper post-translational modification like
glycosylation, these mutations are likely to affect NOTCH1 function. This is also supported by
in silico prediction tools (Table 2).
The impact of the NOTCH1 pathway in the pathogenesis of proximal aortic disease and
BAV was reported in several studies [14,15,22]. Three NOTCH1 variants identified in our
study (i.e., c. 1334C>T (p. T445M), c. 4168C>A (p. P1390T), c. 4028C>T (p. A1343V) were pre-
viously reported in thoracic aortic aneurysms in BAV patients [14,15], as well as in patients
with Adams-Oliver syndrome which is associated with variable cardiac anomalies (i.e., ventric-
ular septal defects, pulmonary atresia) [23]. Similar to the findings in the whole NOTCH (+)
subgroup, there was a tendency towards lower miR-145 expression in the two BAV patients
with the previously published NOTCH1 variants (5.05±0.93 vs. 5.57±0.78, p = 0.25). Further-
more, none of these rare NOTCH1 variants could be identified in the control group of TAV
patients without aortopathy. Corresponding to these findings, TAV patients had significantly
higher miR-145 expression as compared to the BAV study group.
In summary, we provide preliminary data which supports the association the association
between BAV aortopathy, rare NOTCH1 variants, and miR-145 expression. Fig 3 displays the
potential mechanistic link between NOTCH1 variants, miR-145 expression and bicuspid aor-
topathy. However, the final evidence for the proposed genetic pathway has yet to be demon-
strated on the molecular basis.
Although our previous manuscript revealed a wide spectrum of genetic abnormalities in
BAV root phenotype patients [13] we focused here primarily on rare NOTCH1 variants which
was because (a) NOTCH1 variants had the highest frequency as compared to the genetic
abnormalities in the remaining 11 candidate genes; (b) the previously reported potentially
pathogenetic linkage between basal NOTCH1 signaling and miR-145 expression (Fig 3).
In addition, our study findings are in accordance with data published by Wu and co-
authors and indicate that the expression of miR-17-associated miRNAs (a total of 9 miRNAs,
including miR-17 and miR-106a) correlates with the severity of aortopathy [16]. Similar to the
miR-145 expression, miR-17/miR-106a blood levels were significantly downregulated in BAV
patients who experienced the progression of aortopathy during the follow-up.
Study limitations
This study has some limitations. The present miRNAs analysis targeted 11 miRNAs, all previ-
ously reported in association with aortopathy [6,13] and 20 candidate genes known to be
related to aortopathy. A more comprehensive analysis of the whole spectrum of human miR-
NAs and genetic variants, e.g. by sequencing technologies would have enabled us to reveal fur-
ther miRNAs and gene variants potentially associated with the BAV root phenotype and to
expand the list of molecular biomarkers and gene variants potentially relevant to the
MiR-145 in aortopathy
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phenotype. In addition, the functional impact of genetic variants identified remains to be clari-
fied. Furthermore, expression of miR-145 in the aortic tissue would be of great scientific inter-
est and would potentially expand our findings. Unfortunately, our study cohort of BAV root
phenotype was collected over a very long period and no aortic tissue is available in two thirds
of patients.
Although we identified a statistical association between levels of circulating miR-145 and
genetic variants in the NOTCH1 gene in the presented study, further analyses need to be per-
formed to provide the direct link between the cellular expression of miR-145 and NOTCH1
variants.
This study included limited number of BAV patients and therefore needs to be seen as of
preliminary character. We did not include a control group with tricuspid aortopathy and
therefore cannot answer the question whether the differential expression of circulating miR-
NAs is specific for BAV aortopathy. Finally, our patients had their primary operation over a
20-year period, and most of them were in their 60s or 70s at the time of last follow-up. Their
parents were not available for genetic analysis, and the data on siblings and children were
insufficient. Therefore, we unable to get the full picture on the penetrance patterns of identi-
fied variants in the families or substantiate the role of de novo variants in the study cohort.
Conclusions
Our preliminary data demonstrate a significant association between blood miR-145 expression
and the presence of rare NOTCH1 variants. This association may be indicative of a specific
pathogenetic pathway in the development of genetically-triggered bicuspid aortopathy and
highlights the role of specific miRNAs in the transmission of genetic defects inducing
vasculopathy.
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Fig 3. Potential mechanistic linkage between NOTCH1 variants, miR-145 expression and bicuspid aortopathy.
https://doi.org/10.1371/journal.pone.0200205.g003
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